Document is current
Any future updates will be listed below
-
Authors
Haberstroh, Hanna https://orcid.org/0000-0001-8192-8967
Hirsch, Aleksandra
Goldacker, Sigune
Zessack, Norbert
Warnatz, Klaus https://orcid.org/0000-0002-1172-865X
Grimbacher, Bodo https://orcid.org/0000-0002-6897-6806
Salzer, Ulrich https://orcid.org/0000-0002-1769-1157
-
Funding
Funding for this research was provided by:
Baxalta GmbH, a Takeda company
Universitätsklinikum Freiburg
- License Information
-
More Information
Article History
Received: 30 November 2022
Accepted: 2 March 2023
First Online: 21 March 2023
Declarations
:
: Approval was granted by the Institutional Review Board, University of Freiburg #514/18.
: All patients provided informed consent to participate in this study.
: Not applicable—no individual patient’s data are included in this manuscript.
: HH has received a travel grant from Baxalta/Takeda.NZ is an employee and shareholder of Takeda.KW has received an honorarium for speaker engagement from CSL Behring and Takeda and has received royalties for participating in advisory boards for Bristol-Myers Squibb, LFB Biomedicaments, and Takeda.BG has received research funding from Baxalta, a Takeda company, on the topic of the presented research.US has received royalties from Baxalta, a Takeda company, for participation in advisory boards.AH and SG have nothing to disclose.
